Overview
Occlusive stroke results from the obstruction of blood vessels supplying the brain, leading to ischemia and potential tissue damage. This condition can arise from various etiologies including large artery atherosclerosis, small vessel disease, and embolic events 25.Diagnosis
Imaging: CT or MRI to identify infarct location and extent 2.
Angiography: CTA or MRA to assess vascular occlusion and collateral circulation status 2.
Hemodynamic Assessment: Computational fluid dynamics (CFD) models to evaluate translesional pressure gradients and leptomeningeal collateral function 2.
Laboratory Tests: Screening for antiphospholipid antibodies in patients with suspected embolic mechanisms 4.Management
Antiplatelet Therapy: Clopidogrel shown effective in secondary prevention compared to aspirin 3.
Dual Antiplatelet Therapy: Consider modified-release dipyridamole in combination with aspirin for certain patients 3.
Targeted Therapies: Investigational approaches targeting mitochondrial pathways, such as SLC25A33 inhibition, may reduce VSMC proliferation and migration 1.
Management of Risk Factors: Control of hypertension, diabetes, and hyperlipidemia to prevent further vascular occlusions 5.Special Populations
Elderly: Increased risk of occlusive stroke due to cumulative vascular damage; management focuses on aggressive risk factor control 5.
Comorbidities: Presence of systemic conditions like Sneddon's syndrome requires tailored vascular management strategies 5.
Antiphospholipid Syndrome: Higher prevalence of antiphospholipid antibodies in occlusive retinal vascular disorders; anticoagulation may be considered 4.Key Recommendations
Use Clopidogrel for Secondary Prevention: Clopidogrel is favored over aspirin for reducing ischemic stroke, MI, or vascular death in secondary prevention (Evidence: Strong 3).
Evaluate Collateral Circulation: Assess leptomeningeal collateral status using CFD models to guide prognosis and treatment decisions (Evidence: Moderate 2).
Screen for Antiphospholipid Antibodies: Consider screening for antiphospholipid antibodies in patients with embolic mechanisms to guide anticoagulation therapy (Evidence: Moderate 4).
Monitor and Manage Risk Factors: Aggressively manage cardiovascular risk factors in elderly patients to prevent recurrent occlusive events (Evidence: Expert opinion 5).References
1 Kim D, Shin J, Choi YK, Lee YM, Park KG, Kim HS et al.. Targeting SLC25A33 Suppresses Vascular Smooth Muscle Cell Proliferation and Migration by Reducing Cytosolic mtDNA Levels: Implications for Occlusive Vascular Diseases. Diabetes & metabolism journal 2026. link
2 Leng X, Lan L, Ip HL, Fan F, Ma SH, Ma K et al.. Translesional pressure gradient and leptomeningeal collateral status in symptomatic middle cerebral artery stenosis. European journal of neurology 2018. link
3 Jones L, Griffin S, Palmer S, Main C, Orton V, Sculpher M et al.. Clinical effectiveness and cost-effectiveness of clopidogrel and modified-release dipyridamole in the secondary prevention of occlusive vascular events: a systematic review and economic evaluation. Health technology assessment (Winchester, England) 2004. link
4 Carbone J, Sánchez-Ramón S, Cobo-Soriano R, Seoane E, Aparicio MJ, Ruiz-Tíscar JL et al.. Antiphospholipid antibodies: a risk factor for occlusive retinal vascular disorders. Comparison with ocular inflammatory diseases. The Journal of rheumatology 2001. link
5 al Meshari K, al Eisa A, Akhtar M. Sneddon's syndrome: a systemic arterio-occlusive disorder. American journal of kidney diseases : the official journal of the National Kidney Foundation 1995. link90659-2)
6 Brittain RT, Boutal L, Carter MC, Coleman RA, Collington EW, Geisow HP et al.. AH23848: a thromboxane receptor-blocking drug that can clarify the pathophysiologic role of thromboxane A2. Circulation 1985. link
7 Ohtawa T. HLA antigens in arterial occlusive diseases in Japan. The Japanese journal of surgery 1976. link